Wave Life Sciences to Highlight RNA Editing Modality and PRISM Platform Advancements During Upcoming Scientific Conferences
September 07 2021 - 8:30AM
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic
medicines company committed to delivering life-changing treatments
for people battling devastating diseases, today announced it will
highlight its ADAR-mediated RNA editing (“ADAR editing”) capability
and PRISMTM platform advancements at upcoming scientific
conferences. These include the TIDES USA: Oligonucleotides &
Peptide Therapeutics meeting and the 17th Annual Meeting of the
Oligonucleotide Therapeutics Society (OTS), taking place September
20-23, 2021 and September 26-29, 2021, respectively.
“The data we’ll present at this year’s TIDES USA and OTS
meetings underscore the remarkable progress we continue to make
with our pipeline and our platform. Through the resolution provided
by stereochemical control, we have identified new ways to enhance
the pharmacologic profiles of our candidates, including the
application of PN backbone modifications,” said Paul Bolno, MD,
MBA, President and Chief Executive Officer of Wave Life Sciences.
“At OTS, we will also highlight our discovery-stage alpha-1
antitrypsin deficiency program, as well as our leading ADAR editing
modality. These data continue to support our belief that Wave’s
ADAR editing modality has best-in-class potential among RNA editing
approaches due to its versatility and ability to produce precise
and efficient editing in the liver and central nervous system.”
TIDES USA: Oligonucleotides & Peptide Therapeutics
Meeting
- Wednesday, September 22 at 5:00 p.m.
EDT Exploring New Oligonucleotide Backbone
Chemistries and Their Deployment to Improve the Properties of
Stereopure Oligonucleotides (Chandra Vargeese, PhD, Chief
Technology Officer at Wave Life Sciences)Oligonucleotide Discovery
to Clinic & CMC Track: Nucleic Acid Chemical Modifications
- Thursday, September 23 at 8:30 a.m.
EDTEnhancing the Pharmacologic Profiles of CNS Targeting
Therapeutic Oligonucleotides (Elena Dale, PhD, Senior Director,
Head of CNS Biology at Wave Life Sciences)Oligonucleotide Discovery
to Clinic & CMC Track: Oligonucleotides for CNS, Skin Cancer,
NAFLD and Other Indications
- Tuesday, September 21-Thursday, September
23 Impact of Nitrogen-containing Backbone Linkages on
Stereopure Antisense Oligonucleotides in the CNS (Yuanjing Liu,
PhD, Principal Scientist at Wave Life Sciences)Poster Available On
Demand and for Viewing During Exhibit Hours
17th Annual Meeting of the Oligonucleotide Therapeutics
Society
- Tuesday, September 28 at 12:45 p.m.
EDTChemically Optimized Stereopure Oligonucleotides Direct
ADAR-mediated RNA Editing of SERPINA1 Transcripts, Yielding
Functional Alpha-1 Antitrypsin Protein in a Mouse Model for Alpha-1
Antitrypsin Deficiency (Prashant Monian, PhD, Senior Scientist at
Wave Life Sciences) Session VI: Genome and RNA Editing (On
Demand)
- Sunday, September 26-Wednesday, September 29A
Versatile Platform for ADAR-mediated RNA Editing In Vivo in
Preclinical Models (Chikdu Shivalila, PhD, Principal Scientist at
Wave Life Sciences)Poster Available On Demand
- Sunday, September 26-Wednesday, September
29Predicting Exon Criticality from Primary Protein
Structure (Jigar Desai, PhD, Scientist II at Wave Life
Sciences)Poster Available On Demand
- Sunday, September 26-Wednesday, September 29In
Vitro Models for the Assessment of Antisense Oligonucleotide
Induced Hepatotoxicity (Xuena Lin, MD, previously Senior Scientist
II at Wave Life Sciences)Poster Available On Demand
- Sunday, September 26-Wednesday, September
29Impact of Nitrogen-containing Backbone Linkages on
Stereopure Antisense Oligonucleotides in the CNS (Pachamuthu
Kandasamy, PhD, Senior Director, Head of Medicinal Chemistry at
Wave Life Sciences)Poster Available On Demand
- Sunday, September 26-Wednesday, September
29Allele-selective Reduction of Rho P23H-mutant Rhodopsin
Rescues Phenotype Associated with Retinitis Pigmentosa in
Preclinical Models (Michael Byrne, PhD, Senior Director, In Vivo
Biology and Ophthalmology at Wave Life Sciences)Poster Available On
Demand
About PRISM™PRISM is Wave Life Sciences’
proprietary discovery and drug development platform that enables
genetically defined diseases to be targeted with stereopure
oligonucleotides across multiple therapeutic modalities, including
silencing, splicing and editing. PRISM combines the company’s
unique ability to construct stereopure oligonucleotides with a deep
understanding of how the interplay among oligonucleotide sequence,
chemistry and backbone stereochemistry impacts key pharmacological
properties. By exploring these interactions through iterative
analysis of in vitro and in vivo outcomes and machine
learning-driven predictive modeling, the company continues to
define design principles that are deployed across programs to
rapidly develop and manufacture clinical candidates that meet
pre-defined product profiles.
About Wave Life SciencesWave Life Sciences
(Nasdaq: WVE) is a clinical-stage genetic medicines company
committed to delivering life-changing treatments for people
battling devastating diseases. Wave aspires to develop
best-in-class medicines across multiple therapeutic modalities
using PRISM, the company’s proprietary discovery and drug
development platform that enables the precise design, optimization,
and production of stereopure oligonucleotides. Driven by a resolute
sense of urgency, the Wave team is targeting a broad range of
genetically defined diseases so that patients and families may
realize a brighter future. To find out more, please visit
www.wavelifesciences.com and follow Wave on Twitter
@WaveLifeSci.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, as amended,
including, without limitation, the remarkable progress we continue
to make with our pipeline and platform; our belief that our ADAR
editing modality has best-in-class potential; among other
statements. The words “may,” “will,” “could,” “would,” “should,”
“expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,”
“predict,” “project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this
press release are based on management's current expectations and
beliefs and are subject to a number of risks, uncertainties and
important factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, the risks and uncertainties described in the section
entitled “Risk Factors” in Wave’s most recent Annual Report on Form
10-K filed with the Securities and Exchange
Commission (SEC), as amended, and in other filings Wave makes
with the SEC from time to time. Wave undertakes no
obligation to update the information contained in this press
release to reflect subsequently occurring events or
circumstances.
Investor Contact:Kate
Rausch617-949-4827krausch@wavelifesci.com
Media Contact:Alicia
Suter617-949-4817asuter@wavelifesci.com
Wave Life Sciences (NASDAQ:WVE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Wave Life Sciences (NASDAQ:WVE)
Historical Stock Chart
From Apr 2023 to Apr 2024